Anterior|Siguiente

Mecanismo de acción de la decocción de peonía en la regulación de la vía TLR4/MyD88/NF-κB para proteger la barrera mucosa intestinal en la colitis ulcerosa

  • role： First author第一作者
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

    Anhui University of Chinese Medicine， Hefei 230012， China

  • Email：987909401@qq.com
  • Introduction：吴东升，博士，主治医师，从事肠道慢性疾病合并肛周病变的中医药研究，E-mail：987909401@qq.com
WU Dongsheng12,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

  • Email：514867919@qq.com
  • Introduction：张彧，博士，主治医师，从事中医药防治胃肠道疾病的研究，Tel：0731-89669129，E-mail：514867919@qq.com； *
ZHANG Yu1*,  
  • Affiliation：

    Anhui University of Chinese Medicine， Hefei 230012， China

QUAN Wenjing2,  
  • Affiliation：

    Anhui University of Chinese Medicine， Hefei 230012， China

XIONG Wanqing2,  
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

ZOU Bo1,  
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

XIAO Youwei1,  
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

HUANG Ruoru1,  
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

GONG Yan1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Hospital of Hunan University of Chinese Medicine， Changsha 410007， China

  • Email：Caohui001818@sina.com
  • Introduction：曹晖，硕士，主任医师，从事肠道慢性疾病合并肛周病变的研究，Tel：0731-89669129，E-mail：Caohui001818@sina.com
CAO Hui1*

resumen

El objetivo es explorar el papel de la vía de señalización Toll-like receptor 4 (TLR4) / factor de diferenciación mieloide 88 (MyD88) / factor de transcripción nuclear-κB (NF-κB) en el daño de la barrera mucosa intestinal en la colitis ulcerosa y el mecanismo de intervención de la decocción de peonía. Métodos: Se dividieron 60 ratas SD en grupo blanco, grupo modelo, grupo mesalazina (0.42 g·kg⁻¹) y grupos de dosis baja, media y alta de decocción de peonía (11.1, 22.2, 44.4 g·kg⁻¹). Se indujo un modelo de colitis ulcerosa con 2,4,6-trinitrobencenosulfónico (TNBS). Tras el éxito del modelo, se administraron soluciones salinas, mesalazina o decocción de peonía por vía oral durante 7 días según el grupo. Se observaron cambios en la longitud y masa del colon, la morfología patológica del tejido colónico con tinción de hematoxilina-eosina (HE), la expresión de factores inflamatorios IL-8, COX-2, JAM-1, Claudin-1 en el tejido colónico por inmunohistoquímica, y la expresión protéica de TLR4, MyD88, NF-κB mediante Western blot. Resultados: Comparado con el grupo normal, el índice de actividad de la enfermedad (DAI) en el grupo modelo aumentó significativamente (P<0.01), la longitud y masa del colon disminuyeron significativamente (P<0.01), la expresión de proteínas JAM-1 y Claudin-1 en el tejido colónico disminuyó significativamente (P<0.01), mientras que la expresión de IL-8, COX-2, TLR4, MyD88 y NF-κB p65 aumentó significativamente (P<0.01). En comparación con el grupo modelo, los grupos tratados mostraron una reducción significativa del DAI (P<0.05, P<0.01), un aumento significativo en la longitud y masa del colon (P<0.05, P<0.01), un aumento significativo en la expresión de proteínas JAM-1 y Claudin-1 (P<0.01), y una disminución significativa en los niveles de IL-8, COX-2, TLR4, MyD88 y NF-κB p65 (P<0.01). Conclusión: La decocción de peonía puede reducir la inflamación intestinal, mejorar el daño de la mucosa intestinal y proteger la integridad de la barrera intestinal, probablemente relacionado con la regulación de la vía de señalización TLR4/MyD88/NF-κB.

palabra clave

colitis ulcerosa;decocción de peonía;receptor Toll-like 4 (TLR4)/MyD88/NF-κB;barrera mucosa intestinal

References

  1. 1.
    GAJENDRAN M，LOGANATHAN P，JIMENEZ G，et al.A comprehensive review and update on ulcerative colitis［J］.Dis Mon，2019，65（12）：100851.
  2. 2.
    ZHOU M，LU L，XU X，et al.EUK nanozyme-loaded PL&GA coacervate droplets attenuate ulcerative colitis through restoring gut homeostasis and restricting intestinal cell ferroptosis［J］.Mater Today Bio，2025，35：102466.
  3. 3.
    LIU Z，CHEN S，YU J，et al."Golden cicada-escape" style colon-targeted pellets for ulcerative colitis by balancing oxidative stress and repairing colonic barrier［J］.Mater Today Bio，2025，35：102608.
  4. 4.
    ZHENG X，LI L，MA H，et al.Toll-like receptors and their role in the pathogenesis of myasthenia gravis：A comprehensive review［J］.Front Immunol，2025，16：1624957.
  5. 5.
    YANG Q Y，MA L L，ZHANG C，et al.Exploring the mechanism of Indigo naturalis in the treatment of ulcerative colitis based on TLR4/MyD88/NF-κB signaling pathway and gut microbiota［J］.Front Pharmacol，2021，12：674416.
  6. 6.
    LU D X，LIU F，WU H，et al.Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation［J］.World J Gastroenterol，2022，28（32）：4574-4599.
  7. 7.
    DU L，HA C.Epidemiology and pathogenesis of ulcerative colitis［J］.Gastroenterol Clin North Am，2020，49（4）：643-654.
  8. 8.
    WANG Z，LIU T，LIU L，et al.Lactobacillus vaginalis alleviates DSS induced colitis by regulating the gut microbiota and increasing the production of 3-indoleacrylic acid［J］.Pharmacol Res，2025，213：107663.
  9. 9.
    WEI F H，XIE W Y，ZHAO S P，et al.Echinacea purpurea polysaccharide ameliorates dextran sulfate sodium-induced colitis by restoring the intestinal microbiota and inhibiting the TLR4-NF-κB axis［J］.Nutrients，2024，16（9）：1305.
  10. 10.
    LIANG Y，LI Y，LEE C Y，et al.Ulcerative colitis：Molecular insights and intervention therapy［J］.Mol Biomed，2024，5（1）：42.
  11. 11.
    LU H，ZHANG W，WU Z，et al.Advances and prospects of microenvironment-targeted nanotherapeutics for ulcerative colitis：Evolving paradigms in the precision gut microenvironment［J］.Int J Pharm，2026，690：126546.
  12. 12.
    ZHENG Y，LI J，CHEN M Y，et al.Therapeutic efficacy and mechanism of modified Kuijieling in treating ulcerative colitis of spleen deficiency and dampness-stasis syndrome type［J］.Tradit Chin Drug Res Pharmacol，2025，36（12）：2180-2192.
  13. 13.
    XIE N J，WU D S，CAO H，et al.Shaoyaotang alleviates damage of tight junction proteins in Caco-2 cell model of inflammation by regulating RhoA/ROCK pathway［J］.Chin J Exp Tradit Med Form，2025，31（13）：70-77.
  14. 14.
    WU D S，CAO H，CAO X Y，et al.Mechanism of Shaoyaotang in regulating water metabolism and intestinal epithelial permeability in ulcerative colitis through cAMP/PKA/CREB signaling pathway［J］.Chin J Exp Tradit Med Form，2023，29（9）：53-60.
  15. 15.
    WU D S，ZHANG Y，ZOU B，et al.Shaoyao decoction alleviates TNBS-induced ulcerative colitis by decreasing inflammation and balancing the homeostasis of Th17/Treg cells［J］.BMC Complement Med Ther，2023，23（1）：424.
  16. 16.
    WANG W，XU C，LI X，et al.Exploration of the potential mechanism of Banxia Xiexin decoction for the effects on TNBS-induced ulcerative colitis rats with the assistance of network pharmacology analysis［J］.J Ethnopharmacol，2021，277：114197.
  17. 17.
    WU D S，CAO H，ZHANG Y，et al.Shaoyaotang alleviates ulcerative colitis by regulating Th17/Treg balance through IL-6/STAT3 signaling pathway［J］.Chin J Exp Tradit Med Form，2023，29（9）：46-52.
  18. 18.
    WU D S，CAO H，ZHANG Y，et al.Shaoyaotang treats ulcerative colitis by inhibiting HIF-1α and regulating Th17/Treg balance［J］.Chin J Exp Tradit Med Form，2021，27（16）：9-15.
  19. 19.
    ZHANG Y，GE F，QU H，et al.Wumei Wan ameliorates ulcerative colitis in rats by modulating the inflammation-pyroptosis-intestinal stem cell axis［J］.J Ethnopharmacol，2025，355（PA）：120645.
  20. 20.
    ZHU L，LIANG J.Network pharmacological prediction of the mechanism of action of Shen-Zhu-Lian-Bai decoction in the treatment of ulcerative colitis［J］.Sci Rep，2024，14（1）：14183.
  21. 21.
    TIAN Y，LIU Y，SHANG Y，et al.ST3Gal1 modulates intestinal barrier function and impacts human ulcerative colitis［J］.Mol Med Rep，2026，33（2）：73.
  22. 22.
    SOUZA R F，CAETANO M A F，MAGALHAES H I R，et al.Study of tumor necrosis factor receptor in the inflammatory bowel disease［J］.World J Gastroenterol，2023，29（18）：2733-2746.
  23. 23.
    WANG C F，ZHOU T Y，LV L X，et al.Design，semisynthesis，and anti-inflammatory activity evaluation of a terphenyllin compound library for alleviating ulcerative colitis［J］.Eur J Med Chem，2026，305：118539.
  24. 24.
    TAN Y，CAO W，YANG L，et al.Structural characterization of the glucan from Gastrodia elata Blume and its ameliorative effect on DSS-induced colitis in mice［J］.Int J Biol Macromol，2024，275（P2）：133718.
  25. 25.
    JI W，HUO Y，ZHANG Y，et al.Palmatine inhibits expression fat mass and obesity associated protein （FTO） and exhibits a curative effect in dextran sulfate sodium （DSS）-induced experimental colitis［J］.Int Immunopharmacol，2024，132：111968.
  26. 26.
    ZHAO Y Q，ZHANG Y，QIN Y，et al.Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression，with barrier restoration and microbiota modulation［J］.World J Gastroenterol，2026，32（2）：114057.
  27. 27.
    WU D，SHI P，TANG L H，et al.Celastrol alleviates intestinal epithelial permeability by inhibiting ferroptosis through PI3K/Akt/FoxO1/HO-1 signaling pathway［J］.Am J Chin Med，2025，53（4）：1207-1224.
  28. 28.
    ZAMMARCHI I，SANTACROCE G，PUGA-TEJADA M，et al.Epithelial neutrophil localization and tight junction Claudin-2 expression are innovative outcome predictors in inflammatory bowel disease［J］.United European Gastroenterol J，2024，12（9）：1155-1166.
  29. 29.
    LA S，ABAIDULLAH M，LI H，et al.Alfalfa polysaccharide alleviates colitis by regulating intestinal microbiota and the intestinal barrier against the TLR4/MyD88/NF-κB pathway［J］.Nutrients，2025，17（18）：125.
  30. 30.
    HUANG J J，FENG Y M，ZHENG S M，et al.Eugenol possesses colitis protective effects：Impacts on the TLR4/MyD88/NF-κB pathway，intestinal epithelial barrier，and macrophage polarization［J］.Am J Chin Med，2024，52（2）：21-20.
  31. 31.
    ZHU T，SUN S Y，YANG S X，et al.Wheat-grain moxibustion ameliorates ulcerative colitis：Suppressing intestinal inflammation，modulating gut microbiota，and restoring mucosal barrier integrity［J］.J Inflamm Res，2025，18：12619-12636.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website